Hydralazine disease

Hydralazine disease, or so-called hydralazine deficiency syndrome, is a rare but unpleasant condition that can occur in people taking hydralazine-based antihypertensive drugs. This disease is characterized by high blood clotting, an increased risk of blood clots, and an increased risk of heart attack.

Hydralysine disease begins when the body stops producing the necessary enzyme to process hydralysine in the body. Without this enzyme, hydrazine accumulates in the blood and continues to affect the body, causing negative effects. This process can develop in people whose bodies cannot produce hydrazinostase sufficiently. As a result of this syndrome, patients may experience blood clots and cardiac arrest.

Hydralazine disease or hydralysis syndrome is a serious vascular disorder that can lead to a variety of health problems. This is a rare condition, but it does affect many people. Let's look at everything you would like to know about this disease.

Hydralysine disease or hydralamine disease (HD) is a rare vascular disease characterized by the formation of intimal plexuses in small and medium-sized vessels of the microvasculature. Hypertension is combined with fundus hyperemia and a heart murmur—the murmur of mitral insufficiency.

The etiology of the disease is unknown, but a hereditary predisposition is noted: cases of the disease most often occur in families with carriers of the ITGA2 gene, encoding the α_ subunit of integrin a2. Hereditary factors may also include the presence of hypertension, increased levels of homocysteine, antiphospholipid antibodies and changes in plasminogen activator inhibitor type 1 (PAI1) levels [3].

Hypertension is characterized by changes in microhemodynamics, disturbances in the rheological properties of blood, oxidative stress and endothelial dysfunction, which may be caused by polymorphism of the genes for b2-adrenergic receptors, adenosine A2A receptors, endotedin-